{"entity":{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","aka":["TORL Biotherapeutics, LLC"],"tldr":"TORL BioTherapeutics is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing the antibody-drug conjugates TORL-1-23 (ixotatug vedotin) and TORL-5-700 in non-Hodgkin lymphoma and ovarian cancer.","summary":"TORL BioTherapeutics develops antibody-drug conjugates for cancer, drawing on a research partnership with the Slamon laboratory at UCLA. Its lead programme TORL-1-23 (ixotatug vedotin) targets claudin 6 in solid tumours and is in phase 2 for platinum-resistant ovarian cancer; TORL-5-700 is an earlier-stage ADC. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07439653 (phase 1/2, A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma), NCT06690775 (phase 2, CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.) and NCT07322094 (phase 1/2, CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemothera...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://torlbio.com/"},{"label":"ClinicalTrials.gov: trials led by TORL BioTherapeutics","url":"https://clinicaltrials.gov/search?lead=TORL%20Biotherapeutics%2C%20LLC"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["non-hodgkin-lymphoma","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["pegfilgrastim","paclitaxel","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07439653","nct06690775","nct07322094"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Culver City, California","country":"US","companyType":"biotech","website":"https://torlbio.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/torl-biotherapeutics/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/"}],"trial":[{"id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/"},{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/"},{"id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/"}]}}